Effect of a Soluble Fibre Blend and Medium Chain Triglycerides on Body Composition and Cardiometabolic Risk Factors
This study has been completed.
Sponsor:
Canadian Center for Functional Medicine
Collaborator:
University of British Columbia
Information provided by:
Canadian Center for Functional Medicine
ClinicalTrials.gov Identifier:
NCT00644098
First received: March 24, 2008
Last updated: June 21, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate whether the addition of capsules containing soluble fibre complex emulsified with medium chain triglycerides and taken before with meals will lead to a significant amount of weight loss, reduced glycemic volatility and diminished cardio metabolic risk factors in overweight and obese individuals when compared to a placebo control.
We believe that those participants taking 3-6 capsules per day of the treatment capsules over a 14 week period will loose a significant amount of weight compared to the placebo group.
| Condition | Intervention | Phase |
|---|---|---|
|
People Who Are Overweight or Obesity |
Dietary Supplement: soluble fibre complex and medium chain triglycerides |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | The Effect and Dose-response of Soluble Fibre Blend and Medium Chain Triglycerides (MCT) on Body Composition and Cardiometabolic Risk Factors in Overweight and Obese Adults: a Double-blind, Placebo-controlled Study. |
Resource links provided by NLM:
Further study details as provided by Canadian Center for Functional Medicine:
Primary Outcome Measures:
- weight loss [ Time Frame: baseline, biweekly and final visit ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- glycemic volatility and cardio metabolic risk factors [ Time Frame: baseline and final visit ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 150 |
| Study Start Date: | September 2008 |
| Study Completion Date: | August 2009 |
| Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 20 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- BMI 27 - 35 kg/m2
Exclusion Criteria:
-
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00644098
Locations
| Canada, British Columbia | |
| Canadian Center for Functional Medicine | |
| Coquitlam, British Columbia, Canada | |
Sponsors and Collaborators
Canadian Center for Functional Medicine
University of British Columbia
Investigators
| Principal Investigator: | Timothy Durance, PhD | University of British Columbia |
More Information
No publications provided
| Responsible Party: | Dr. Michael Lyon, Canadian Center for Functional Medicine |
| ClinicalTrials.gov Identifier: | NCT00644098 History of Changes |
| Other Study ID Numbers: | 002 |
| Study First Received: | March 24, 2008 |
| Last Updated: | June 21, 2011 |
| Health Authority: | Canada: Health Canada |
Additional relevant MeSH terms:
|
Obesity Overweight Overnutrition |
Nutrition Disorders Body Weight Signs and Symptoms |
ClinicalTrials.gov processed this record on June 17, 2013